TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11464223
Drug: Mayonnaise containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mayonnaise containing phytosterols (PS) dissolved in diacylglycerol (DG) (500 mg/day PS, 10 g/day DG)
Study: 11464223
Drug: Mayonnaise containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mayonnaise containing phytosterols (PS) dispersed in triacylglycerol (TG) (500 mg/day PS, 10 g/day TG)
Study: 7602354
Drug: Edatrexate (EDX)
Normalized name: EDX-502
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edatrexate (EDX) at an initial dose of 80 mg/m2/wk (later reduced to 70 mg/m2/wk)
Study: 7602354
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) at a dose of 40 mg/m2/wk
Study: 20641058
Drug: Red ginseng
Normalized name: Red ginseng
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red ginseng extract (3 g/day)
Study: 15061827
Drug: Rivastigmine treatment
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine treatment for 12 months
Study: 11258692
Drug: Inhaled anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled anti-inflammatory medication (inhaled steroids)
Study: 11770189
Drug: Raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (60 mg per day for 6 months)
Study: 11770189
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined hormone replacement therapy (ccHRT: 2 mg estradiol and 1 mg norethisterone acetate per day for 6 months)
Study: 3468226
Drug: Propoxyphene napsylate
Normalized name: Propoxyphene Napsylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propoxyphene napsylate 100 mg + Acetaminophen 650 mg
Study: 2199415
Drug: Single-dose antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose antibiotic prophylaxis for contaminated head and neck cases and endonasal sinus surgery
Study: 2199415
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic prophylaxis for most clean cases
Study: 31902533
Drug: Computer-aided design
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-aided design and computer-aided manufacturing (CAD-CAM) lithium disilicate crowns (CC)
Study: 31902533
Drug: Biological complications
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological complications for crowns
Study: 31902533
Drug: Biological complications
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological complications for FPDs
Study: 31064365
Drug: COSMOS intervention
Normalized name: Cosmos sulphureus flowering top extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: COSMOS intervention (educational programs, training in clinical evaluation, interprofessional medication review with collegial mentoring)
Study: 28914503
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel (testosterone replacement therapy, n = 20)
Study: 17515584
Drug: Unblinding of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unblinding of treatment name
Study: 7651068
Drug: Gentamicin 4
Normalized name: gentamicin 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 4 mg/kg by infusion over 30 minutes once daily (Single-Dose Group, SG) (N = 25)
Study: 7651068
Drug: Gentamicin 2
Normalized name: gentamicin 2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 2 mg/kg intravenously twice daily (Double-Dose Group, DG) (N = 29)
Study: 16791
Drug: Ketazolam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketazolam (15 mg capsules, flexible dosage range of 15-75 mg, average optimum therapeutic dose of 46.9 mg once daily at bedtime)
Study: 26590478
Drug: Active rTMS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active rTMS (1-Hz) combined with NRT (21-mg patch) for 2 weeks
Study: 26590478
Drug: Sham rTMS
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham rTMS combined with NRT (21-mg patch) for 2 weeks
Study: 20642485
Drug: Ozone therapy
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone therapy (4 to 7 mL of oxygen ozone mixture)
Study: 20642485
Drug: Ozone-PIRFT (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone-PIRFT (combined oxygen-ozone therapy with radiofrequency lesioning at 80°C for 360 s)
Study: 17893293
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen 0.625 mg/medroxyprogesterone acetate 2.5 mg for 4 months
Study: 9877000
Drug: Repaglinide 2
Normalized name: repaglinide 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide 2 mg as tablet
Study: 9877000
Drug: Repaglinide 2
Normalized name: repaglinide 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide 2 mg as oral solution
Study: 9877000
Drug: Repaglinide 2
Normalized name: repaglinide 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide 2 mg as intravenous infusion
Study: 7975854
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (rapid schedule: vaccination at 0, 1, 2 and 12 months)
Study: 7975854
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (standard schedule: vaccination at 0, 1, and 6 months)
Study: 7975854
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (rapid schedule)
Study: 7975854
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (standard schedule)
Study: 27547757
Drug: Desflurane anaesthesia
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desflurane anaesthesia (1 MAC) + propofol infusion (2-3 mg/kg/h)
Study: 27547757
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion (5-6 mg/kg/h)
Study: 25112085
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg, three times per day)
Study: 17505263
Drug: Recombinant interferon
Normalized name: Recombinant Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant interferon alpha-2b (9,000,000,000 IU weekly administered twice daily) and coenzyme Q10 (400 mg/day)
Study: 17505263
Drug: Recombinant interferon
Normalized name: Recombinant Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant interferon alpha-2b (9,000,000,000 IU weekly administered twice daily)
Study: 9836549
Drug: L-arginine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (3 or 10 g daily for 5 weeks)
Study: 31111580
Drug: High-dose dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dual therapy without bismuth (esomeprazole 40 mg twice a day plus amoxicillin 1 g three times a day)
Study: 24621858
Drug: Intramuscular (i.m.)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (i.m.) administration of DNA vaccine (4 mg) and rAd5 (1010 PU)
Study: 24621858
Drug: Subcutaneous (s.c.)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (s.c.) administration of DNA vaccine (4 mg) and rAd5 (1010 PU)
Study: 24621858
Drug: Intradermal (i.d.)
Normalized name: IOBENGUANE I 123
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (i.d.) administration of DNA vaccine (0.4 mg) and rAd5 (1010 PU)
Study: 23363065
Drug: Bosentan 125
Normalized name: bosentan 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan 125 mg twice a day for 4 weeks
Study: 21039220
Drug: 4 doses
Normalized name: parathyroid hormone 25 MCG/Dose Cartridge, 14 Doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 doses of twice-yearly, increased-dose albendazole-ivermectin therapy (800 mg and 400 μg/kg; n = 25)
Study: 21039220
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of annual, standard-dose albendazole-ivermectin therapy (400 mg and 150 μg/kg; n = 26)
Study: 21039220
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (high-dose and standard-dose)
Study: 19043154
Drug: Waiting list
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting list followed by 15 sessions of therapist cognitive-behavioural therapy (CBT)
Study: 15963389
Drug: Bivalirudin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin with provisional GP IIb/IIIa inhibitors
Study: 10789668
Drug: Ketoconazole 400
Normalized name: ketoconazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 400 mg/d for up to 21 days
Study: 8842277
Drug: Cefonicid prophylaxis
Normalized name: cefonicid
DrugBank: Cefonicid (DB01328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefonicid prophylaxis (1 g intravenously) 1 hour before the procedure
Study: 23161038
Drug: L-arginine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (2 g tid or 4 g tid)
Study: 20123315
Drug: Rolofylline 30
Normalized name: Rolofylline
DrugBank: Rolofylline (DB12670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rolofylline 30 mg intravenously daily for 3 days
Study: 18308809
Drug: High-dose ATD
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ATD
Study: 18308809
Drug: Low-dose ATD
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ATD
Study: 12036724
Drug: HPMC capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPMC capsules (oral administration)
Study: 12036724
Drug: HPMC capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPMC capsules (rectal administration)
Study: 12036724
Drug: Gelatine capsules
Normalized name: Gelatin
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatine capsules (oral administration)
Study: 12036724
Drug: Gelatine capsules
Normalized name: Gelatin
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatine capsules (rectal administration)
Study: 12036724
Drug: HPMC capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPMC capsules (various viscosity grades)
Study: 10520777
Drug: Recombinant hirudin
Normalized name: hirudin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant hirudin (lepirudin, i.v. bolus of 0.2 mg/kg, followed by s.c. injections of 0.5 mg/kg b.i.d. for 5 to 7 days)
Study: 10520777
Drug: Heparin (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (i.v. placebo bolus, followed by s.c. injections of 12,500 IU b.i.d. for 5 to 7 days)
Study: 7872337
Drug: Oral ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ofloxacin 400 mg immediately and twice daily thereafter (outpatient management)
Study: 7872337
Drug: Oral ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ofloxacin 400 mg immediately and twice daily thereafter (inpatient management)
Study: 2779095
Drug: Gemfibrozil 600
Normalized name: gemfibrozil 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil 600 mg twice a day
Study: 2779095
Drug: Gemfibrozil plus
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gemfibrozil plus colestipol 10 grams twice a day
Study: 31570942
Drug: Diversion group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diversion group (blood drawn into lithium heparin tube before blood culture bottles)
Study: 31570942
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (blood cultures first, then lithium heparin tube)
Study: 27883209
Drug: Tongue-to-palate resistance
Normalized name: beef tongue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongue-to-palate resistance training (TPRT) for 4 weeks (5 days per week) plus traditional dysphagia therapy
Study: 27883209
Drug: TPRT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPRT plus traditional dysphagia therapy
Study: 21969643
Drug: Bupropion sustained-release
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion sustained-release plus escitalopram
Study: 21969643
Drug: Venlafaxine extended-release
Normalized name: Desvenlafaxine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine extended-release plus mirtazapine
Study: 21800009
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg aspirin BID
Study: 21800009
Drug: 320 mg
Normalized name: aspirin 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320 mg aspirin OD
Study: 19380597
Drug: Pagibaximab (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pagibaximab (10, 30, 60, or 90 mg/kg of body weight)
Study: 16271272
Drug: Regimen I:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen I: oral praziquantel (40 mg/kg body weight)
Study: 16271272
Drug: Regimen II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen II: oral ivermectin (200 microg/kg body weight) with oral albendazole (400 mg)
Study: 16271272
Drug: Regimen III:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen III: oral ivermectin with oral albendazole and praziquantel
Study: 16271272
Drug: Concurrent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent administration of all three drugs (albendazole, praziquantel, ivermectin)
Study: 9052592
Drug: Treatment according
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment according to established protocol (physician‐chosen combinations of intracervical or vaginal prostaglandins every 4‐6 hours, artificial rupture of membranes, and oxytocin infusion)
Study: 8498881
Drug: Alprazolam 0.25
Normalized name: alprazolam 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 0.25 mg three times daily from menstrual cycle day 16
Study: 8498881
Drug: Alprazolam 0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 0.50 mg three times daily
Study: 8498881
Drug: Alprazolam 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 0.75 mg three times daily from menstrual cycle day 16
Study: 30255720
Drug: Intravenous delta-9-tetrahydrocannabinol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous delta-9-tetrahydrocannabinol (0.015 mg/kg)
Study: 30255720
Drug: Intravenous delta-9-tetrahydrocannabinol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous delta-9-tetrahydrocannabinol (0.03 mg/kg)
Study: 21492884
Drug: Cinacalcet 60
Normalized name: cinacalcet 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet 60 mg single dose
Study: 21036880
Drug: Sorafenib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (400 mg bid) combined with TACE (doxorubicin 50 mg)
Study: 21036880
Drug: Sorafenib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (200 mg bid)
Study: 18408077
Drug: Renilon 7.5(R)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renilon 7.5(R) oral supplement, 2 packs of 125-ml daily for 3 months
Study: 15936131
Drug: Swanson metacarpophalangeal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swanson metacarpophalangeal implants
Study: 15936131
Drug: Sutter metacarpophalangeal
Normalized name: Cocoa Butter
DrugBank: Cocoa butter (DB11086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sutter metacarpophalangeal implants
Study: 1803828
Drug: Danazol 600
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Danazol 600 mg/daily for 3 months plus local immunosuppressive treatment combined with superovulation and IPI
Study: 6819028
Drug: Vitamin-only supplementation
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin-only supplementation (vitamin C 30 mg daily, iron 3 mg daily)
Study: 25461789
Drug: Computer-Based Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-Based Training for Cognitive Behavioral Therapy (CBT4CBT)
Study: 9930401
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) supplementation (0.8 g x 3 capsules/d)
Study: 9930401
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil with vitamin E (FOE) supplementation (0.8 g x 3 capsules/d with 3 IU/g vitamin E)
Study: 31948337
Drug: Breakfast meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breakfast meal with 9 g fat and 25 g sugar
Study: 31948337
Drug: Breakfast meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breakfast meal with 28 g fat and 18 g sugar
Study: 31948337
Drug: Breakfast meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breakfast meal with 5 g fat and 56 g sugar
Study: 28893130
Drug: Bite&White treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bite&White treatment
Study: 26541501
Drug: Motivational enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational enhancement therapy delivered in Spanish (MET‐S)
Study: 26541501
Drug: Motivational enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational enhancement therapy delivered in English (MET‐E)
Study: 18300985
Drug: Ketorolac and
Normalized name: Ketorolac and phenylephrine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac and bupivacaine (30 mg and 150 mg, respectively)
Study: 17030772
Drug: Self-administered ALSFRS-R
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered ALSFRS-R
Study: 17030772
Drug: Standard evaluator-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard evaluator-administered ALSFRS-R
Study: 12728215
Drug: Formulated soy
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulated soy stanols (1.9 g) in a lemonade-flavored beverage
Study: 12728215
Drug: Formulated soy
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulated soy stanols (1.9 g) in egg whites
Study: 1637574
Drug: Intravenous salcatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous salcatonin (100 U/d, continuous infusion for five days)
Study: 1637574
Drug: Intramuscular salcatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular salcatonin (100 U/d, single bolus for five days)
Study: 6425913
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg d‐amphetamine
Study: 6425913
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of d‐amphetamine
Study: 20436049
Drug: Non-compliance with
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-compliance with daily weighing
Study: 11932310
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment for 7 days
Study: 11932310
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment for 12 months
Study: 2122026
Drug: ILB method
Approvals — FDA: no, EMA: no, PMDA: no
Description: ILB method (gentamicin mixed using total nutrient admixture solution)
Study: 26217065
Drug: BMAC infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BMAC infusion in NIHF group
Study: 26217065
Drug: BMAC infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BMAC infusion in IHF group
Study: 17142929
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral treatment with 5 mg of folate and 1,500 microg of mecobalamin
Study: 12798401
Drug: Screening by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening by oral visual inspection by trained health workers at 3-year intervals
Study: 1607550
Drug: Intranasal triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal triamcinolone acetonide aerosol (ITAA) 220 micrograms/day
Study: 1607550
Drug: Intranasal triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal triamcinolone acetonide aerosol (ITAA) 440 micrograms/day
Study: 6382361
Drug: Moclobemide (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (mean daily dose 297 mg, treatment duration 2-4 weeks)
Study: 29350840
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate sinus implants
Study: 27907074
Drug: Group-based acceptance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based acceptance and commitment therapy (ACT)
Study: 24393423
Drug: Step count
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Step count prescription with pedometers, aiming to increase counts by ≥3,000 steps/day over one year, with individualized rate increase.
Study: 22081474
Drug: Scheduled infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Scheduled infliximab (IFX) at 5 mg/kg intravenously every 8 weeks for 36 months
Study: 20613538
Drug: Goal-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed therapy (groups 2 and 3) aiming to maintain the pulse contour-derived cardiac index above 2.5 l m min.
Study: 17992069
Drug: Health diary
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health diary program (50 minutes, twice a week for 8 weeks)
Study: 11806971
Drug: 200 mg/m(2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/m(2) melphalan (arm B)
Study: 11806971
Drug: 8 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 Gy total body irradiation plus 140 mg/m(2) melphalan (arm A)
Study: 7857101
Drug: 5'‐DFUR (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5'‐DFUR (daily dose 800 mg for 3 days)
Study: 7857101
Drug: UFT (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (daily dose 600 mg for 3 days)